Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNotes PayablesOther Accumulated ExpensesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal Liabilities
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Universe Pharmaceuticals (UPC) Non-Current Assets (2021 - 2025)

Universe Pharmaceuticals' Non-Current Assets history spans 5 years, with the latest figure at -$53.6 billion for Q3 2025.

  • For Q3 2025, Non-Current Assets fell 328642.29% year-over-year to -$53.6 billion; the TTM value through Sep 2024 reached $16.3 million, down 0.85%, while the annual FY2025 figure was -$53.6 billion, 328642.29% down from the prior year.
  • Non-Current Assets for Q3 2025 was -$53.6 billion at Universe Pharmaceuticals, down from $16.3 million in the prior quarter.
  • Across five years, Non-Current Assets topped out at $19.7 million in Q3 2021 and bottomed at -$53.6 billion in Q3 2025.
  • The 5-year median for Non-Current Assets is $16.5 million (2023), against an average of -$10.7 billion.
  • The largest annual shift saw Non-Current Assets decreased 0.85% in 2024 before it plummeted 328642.29% in 2025.
  • A 5-year view of Non-Current Assets shows it stood at $19.7 million in 2021, then dropped by 8.29% to $18.0 million in 2022, then decreased by 8.76% to $16.5 million in 2023, then fell by 0.85% to $16.3 million in 2024, then tumbled by 328642.29% to -$53.6 billion in 2025.
  • Per Business Quant, the three most recent readings for UPC's Non-Current Assets are -$53.6 billion (Q3 2025), $16.3 million (Q3 2024), and $16.5 million (Q3 2023).